001     147218
005     20240229112643.0
024 7 _ |a 10.1148/radiol.2019190938
|2 doi
024 7 _ |a pmid:31592731
|2 pmid
024 7 _ |a 0033-8419
|2 ISSN
024 7 _ |a 1527-1315
|2 ISSN
024 7 _ |a altmetric:68045045
|2 altmetric
037 _ _ |a DKFZ-2019-02344
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Schelb, Patrick
|0 P:(DE-He78)4b5e5faa688c6b833c70b6777f91f662
|b 0
|e First author
|u dkfz
245 _ _ |a Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment.
260 _ _ |a Oak Brook, Ill.
|c 2019
|b Soc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1626959192_3042
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2019 Dec;293(3):607-617
520 _ _ |a Background Men suspected of having clinically significant prostate cancer (sPC) increasingly undergo prostate MRI. The potential of deep learning to provide diagnostic support for human interpretation requires further evaluation. Purpose To compare the performance of clinical assessment to a deep learning system optimized for segmentation trained with T2-weighted and diffusion MRI in the task of detection and segmentation of lesions suspicious for sPC. Materials and Methods In this retrospective study, T2-weighted and diffusion prostate MRI sequences from consecutive men examined with a single 3.0-T MRI system between 2015 and 2016 were manually segmented. Ground truth was provided by combined targeted and extended systematic MRI-transrectal US fusion biopsy, with sPC defined as International Society of Urological Pathology Gleason grade group greater than or equal to 2. By using split-sample validation, U-Net was internally validated on the training set (80% of the data) through cross validation and subsequently externally validated on the test set (20% of the data). U-Net-derived sPC probability maps were calibrated by matching sextant-based cross-validation performance to clinical performance of Prostate Imaging Reporting and Data System (PI-RADS). Performance of PI-RADS and U-Net were compared by using sensitivities, specificities, predictive values, and Dice coefficient. Results A total of 312 men (median age, 64 years; interquartile range [IQR], 58-71 years) were evaluated. The training set consisted of 250 men (median age, 64 years; IQR, 58-71 years) and the test set of 62 men (median age, 64 years; IQR, 60-69 years). In the test set, PI-RADS cutoffs greater than or equal to 3 versus cutoffs greater than or equal to 4 on a per-patient basis had sensitivity of 96% (25 of 26) versus 88% (23 of 26) at specificity of 22% (eight of 36) versus 50% (18 of 36). U-Net at probability thresholds of greater than or equal to 0.22 versus greater than or equal to 0.33 had sensitivity of 96% (25 of 26) versus 92% (24 of 26) (both P > .99) with specificity of 31% (11 of 36) versus 47% (17 of 36) (both P > .99), not statistically different from PI-RADS. Dice coefficients were 0.89 for prostate and 0.35 for MRI lesion segmentation. In the test set, coincidence of PI-RADS greater than or equal to 4 with U-Net lesions improved the positive predictive value from 48% (28 of 58) to 67% (24 of 36) for U-Net probability thresholds greater than or equal to 0.33 (P = .01), while the negative predictive value remained unchanged (83% [25 of 30] vs 83% [43 of 52]; P > .99). Conclusion U-Net trained with T2-weighted and diffusion MRI achieves similar performance to clinical Prostate Imaging Reporting and Data System assessment. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Padhani and Turkbey in this issue.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Kohl, Simon
|0 P:(DE-He78)a35f3fa04c359e037b2377f96920f93f
|b 1
700 1 _ |a Radtke, Jan Philipp
|0 P:(DE-He78)79897f8897ff77676549d9895258a0f2
|b 2
700 1 _ |a Wiesenfarth, Manuel
|0 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
|b 3
700 1 _ |a Kickingereder, Philipp
|0 P:(DE-He78)3da06896bf2a50a84d40c33c3b7a9b3e
|b 4
700 1 _ |a Bickelhaupt, Sebastian
|0 P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9
|b 5
700 1 _ |a Kuder, Tristan Anselm
|0 P:(DE-He78)59dfdd0ee0a7f0db81535f0781a3a6d6
|b 6
700 1 _ |a Stenzinger, Albrecht
|0 0000-0003-1001-103X
|b 7
700 1 _ |a Hohenfellner, Markus
|b 8
700 1 _ |a Schlemmer, Heinz-Peter
|0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
|b 9
700 1 _ |a Maier-Hein, Klaus
|0 P:(DE-He78)33c74005e1ce56f7025c4f6be15321b3
|b 10
700 1 _ |a Bonekamp, David
|0 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
|b 11
|e Last author
773 _ _ |a 10.1148/radiol.2019190938
|g p. 190938 -
|0 PERI:(DE-600)2010588-5
|n 3
|p 607-617
|t Radiology
|v 293
|y 2019
|x 1527-1315
909 C O |p VDB
|o oai:inrepo02.dkfz.de:147218
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)4b5e5faa688c6b833c70b6777f91f662
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)a35f3fa04c359e037b2377f96920f93f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)79897f8897ff77676549d9895258a0f2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)3da06896bf2a50a84d40c33c3b7a9b3e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)59dfdd0ee0a7f0db81535f0781a3a6d6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)33c74005e1ce56f7025c4f6be15321b3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Imaging and radiooncology
|x 0
913 2 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b RADIOLOGY : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b RADIOLOGY : 2017
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 1 _ |0 I:(DE-He78)E230-20160331
|k E230
|l E230 Medizinische Bildverarbeitung
|x 1
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 2
920 1 _ |0 I:(DE-He78)E250-20160331
|k E250
|l Muliparametrische Methoden zur Früherkennung des Prostatakarzinoms
|x 3
920 1 _ |0 I:(DE-He78)E020-20160331
|k E020
|l E020 Med. Physik in der Radiologie
|x 4
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 5
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)E230-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)E250-20160331
980 _ _ |a I:(DE-He78)E020-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21